risperidone has been researched along with Chronic Disease in 171 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 9.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 9.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| "The present findings suggest that clozapine demonstrates superior antidepressant effects to quetiapine and comparable effects to olanzapine and risperidone in chronic schizophrenia regardless of presence of MDE." | 9.20 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. ( Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2015) |
| "We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia." | 9.19 | A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. ( Akhondzadeh, S; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Pourmahmoud, H; Rezaei, F; Sabzabadi, M; Salehi, B; Tabrizi, M; Yekehtaz, H, 2014) |
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 9.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "The objective of this study was to assess the efficacy and tolerability of tropisetron add-on to risperidone on negative symptoms in patients with chronic stable schizophrenia." | 9.17 | A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghasemi, S; Hosseini, SM; Khodaie-Ardakani, MR; Mirshafiee, O; Modabbernia, A; Noroozian, M; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M; Yekehtaz, H, 2013) |
| "In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms." | 9.16 | A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. ( Ahmadi-Abhari, SA; Akhondzadeh, S; Arbabi, M; Bagheri, M; Khalighi-Sigaroudi, F; Rezaei, F; Tabrizi, M, 2012) |
| "Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals." | 9.16 | Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. ( Butcher, B; Emmerson, B; Hustig, H; Jacobs, A; Lambert, T; Resseler, S, 2012) |
| "Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia." | 9.15 | Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. ( Khan, A; Lindenmayer, JP, 2011) |
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 9.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator." | 9.14 | Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. ( Haug, HJ; Kolb, SA; Koponen, H; Lublin, H; Sigmundsson, T, 2009) |
| "Comparisons of diabetic potential, glucose related metabolic levels, and insulin resistance between olanzapine and risperidone have produced variable results in cross-sectional and epidemiologic studies." | 9.14 | Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009) |
| "The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia." | 9.14 | A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. ( Akhondzadeh, S; Farnaghi, F; Ghaleiha, A; Hajiazim, M; Noorbala, AA, 2010) |
| "It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia." | 9.13 | Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Amiri, A; Derakhshan, MK; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Nejatisafa, AA; Noorbala, AA; Raznahan, M, 2008) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 9.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| "When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine." | 9.12 | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason." | 9.12 | Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 9.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 9.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| "To evaluate the clinical efficacy of modified Daotan Decoction (DD) combining low dosage of risperidone in treating chronic schizophrenia patients of phlegm-dampness blockage type, and compare with patients treated with risperidone alone." | 9.12 | [Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia]. ( Liu, JL; Ma, L; Wang, Y, 2007) |
| "Treatment outcome was evaluated in outpatients with chronic schizophrenia during long-term administration of risperidone in a study reflecting clinical practice." | 9.11 | Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. ( Libretto, SE; Reveley, MA, 2004) |
| "We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone." | 9.10 | Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. ( Higuchi, H; Shimizu, T; Sugita, T; Takahashi, H, 2002) |
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 9.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 9.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 9.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "There is little information regarding the effects of risperidone addition to neuroleptic treatment in chronic schizophrenia." | 9.09 | Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. ( Oga, T; Okada, M; Takahashi, N; Terao, T, 1999) |
| "This study compared the long-term (12 months) effectiveness of risperidone (RP) with that of conventional neuroleptics (CNs) in a population with chronic schizophrenia who had shown suboptimal response to CNs." | 9.09 | Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. ( Bouchard, RH; Cliche, D; Demers, MF; Filteau, MJ; Gauthier, Y; Labelle, A; Maziade, M; Mérette, C; Pourcher, E; Roy, MA; Roy-Gagnon, MH; Villeneuve, J, 2000) |
| "This prospective, double-blind, multicenter, parallel-group study compared the efficacy and safety of therapeutic doses of clozapine and risperidone in patients with severe chronic schizophrenia and poor previous treatment response." | 9.09 | A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. ( Azorin, JM; Bourdeix, I; Giguere, M; Péré, JJ; Remington, G; Spiegel, R; Vanelle, JM, 2001) |
| "Given the renewed interest in the role of sex differences in schizophrenia, we undertook a post hoc analysis to determine whether sex differences in treatment response were present among outpatients with schizophrenia who received risperidone in an 8-week, open-label, Phase IV clinical study." | 9.09 | Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. ( Dunbar, F; Labelle, A; Light, M, 2001) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 9.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 9.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "Although risperidone has been shown to be an effective antipsychotic medication in schizophrenia, the clinical studies performed for the Food and Drug Administration's approval process focused on only a mixed group of schizophrenic patients." | 9.08 | Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. ( Bhattacharyya, A; Chua, JW; Lipetsker, B; Smith, RC, 1996) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 9.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "In a controlled double-blind, multicenter study, 86 inpatients with chronic schizophrenia (DSM-III-R), who were resistant to or intolerant of conventional neuroleptics, were randomly assigned to receive risperidone or clozapine for 8 weeks after a 7-day washout period." | 9.08 | Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. ( Baumann, P; Billeter, U; Bondolfi, G; Dufour, H; Eap, CB; May, JP; Patris, M, 1998) |
| "Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia." | 9.08 | Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. ( Beauclair, L; Chouinard, G; Johnson, SV; Kopala, L; Labelle, A; Singh, KI, 1998) |
| " This study sought to explore the characteristics of white matter structural networks in chronic never-treated schizophrenia and those treated with clozapine or risperidone, and its potential association with cognitive function." | 7.96 | Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated. ( Gong, Q; Hu, N; Lencer, R; Li, S; Lui, S; Luo, C; Xiao, Y; Zhang, W, 2020) |
| " risperidone long acting injectable (RLAI), paliperidone long acting injectable (PLAI) and olanzapine long acting injectable (OLAI) in the maintenance treatment of chronic, stable schizophrenia patients in the United Kingdom." | 7.81 | Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. ( Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M, 2015) |
| " The aim of this work was designed to investigate the diagnostic possibility of [(123)I]epidepride imaging platform for risperidone-treatment chronic MK-801-induced rat schizophrenia model." | 7.80 | Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. ( Chang, KW; Chen, MW; Cheng, KH; Huang, YR; Kuo, WI; Pai, CW, 2014) |
| "To evaluate the efficacy and tolerability of long-acting risperidone injection in Thai patients with chronic schizophrenia for 12 weeks treatment." | 7.76 | Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. ( Arunpongpaisal, S; Kitiwattanagul, K; Kongsakon, R; Samanwongthai, U; Srisurapanont, M, 2010) |
| "A 31-year-old patient suffering from schizophrenic psychosis was treated with risperidone, and developed priapism which required surgical intervention and resulted in long-term erectile dysfunction." | 7.74 | Risperidone-induced priapism. ( Makesar, D; Thome, J, 2007) |
| "We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism." | 7.73 | Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 7.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| "The effect of mirtazapine on steady-state plasma concentrations of the newer atypical antipsychotics clozapine, risperidone and olanzapine was investigated in 24 patients with chronic schizophrenia." | 7.72 | Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. ( Canale, A; Crucitti, D; D'Arrigo, C; Malara, G; Muscatello, MR; Spina, E; Torre, DL; Zoccali, R, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "An open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia." | 7.70 | Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. ( Addington, DE; Gagiano, CA; Gaussares, C; Möller, HJ; Torres-Plank, JF; Von Knorring, L, 1998) |
| "Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment." | 7.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| "To determine whether or not risperidone is efficacious in treating self-induced water intoxication in patients with chronic schizophrenia." | 7.69 | Self-induced water intoxication treated with risperidone. ( Emes, CE; Glackman, WG; Millson, RC, 1996) |
| "A prospective, open-label study in a 400-bed state psychiatric hospital evaluated change in therapeutic response among ten patients with treatment-resistant schizophrenia who were switched from clozapine to risperidone." | 7.69 | Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. ( Crismon, ML; Dorson, PG; Pousson, C; Still, DJ, 1996) |
| " Most frequently reported treatment-related adverse events (ie, ≥5% of patients in either TV-46000 group) that occurred more often in patients receiving TV-46000 (once monthly or once every 2 months) versus placebo were injection site nodules (7% for TV-46000 once monthly, 7% for TV-46000 once every 2 months, 3% for placebo), weight increased (4%, 6%, 2%, respectively), and extrapyramidal disorder (5%, 3%, 0% respectively)." | 7.30 | Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. ( Correll, CU; Davis, GL; Eshet, R; Franzenburg, KR; Harary, E; Kane, JM; Leucht, S; Merenlender-Wagner, A; Sharon, N; Suett, M; Tohami, O; Weiser, M, 2023) |
| "Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 6.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
| "Propentofylline is a novel xantine derivative which is being developed for treatment of degenerative and vascular dementia." | 6.73 | A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. ( Abbasi, SH; Ahmadi-Abhari, SA; Akhondzadeh, S; Derakhshan, MK; Fotouhi, A; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Mohammadi, MR; Noorbala, AA; Salimi, S, 2008) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 6.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| "Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments." | 6.70 | Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. ( Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 6.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "Risperidone treatment significantly increased the serum PRL levels of schizophrenic patients." | 6.70 | Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. ( Shen, YC; Wu, GY; Yuan, CL; Zhang, PY; Zhang, XY; Zhou, DF, 2002) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 5.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| "Patients with an acute episode of schizophrenia (n=11) and predominating positive symptoms were randomized to a 6-week add-on treatment with memantine (10 mg twice a day) versus placebo and patients with chronic schizophrenia (n=13) and negative symptoms were randomized to a 24-week add-on treatment with memantine (10 mg twice a day) versus placebo." | 5.34 | Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia. ( Gallinat, J; Heinz, A; Leopold, K; Sarkar, S; Schaefer, M; Theophil, I, 2020) |
| " Failure in switching to monotherapy was associated with higher dosage of antipsychotics at baseline." | 5.33 | Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. ( Kunugi, H; Murray, RM; Nakanishi, S; Nojima, S; Ogawa, T; Takahashi, T, 2006) |
| "96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4." | 5.31 | Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. ( Boscati, L; Laini, V; Mauri, MC; Orlandi, R; Papa, P; Rudelli, R; Salvi, V, 2001) |
| "In this randomized, double-blind, placebo-controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks." | 5.22 | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. ( Akhondzadeh, S; Esalatmanesh, S; Farokhnia, M; Goguol, A; Iranpour, N; Khodaie-Ardakani, MR; Mohammadinejad, P; Salehi, B; Yekehtaz, H; Zandifar, A; Zeinoddini, A; Zeionoddini, A, 2016) |
| "The present findings suggest that clozapine demonstrates superior antidepressant effects to quetiapine and comparable effects to olanzapine and risperidone in chronic schizophrenia regardless of presence of MDE." | 5.20 | Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data. ( Caravaggio, F; Chung, JK; Fervaha, G; Gerretsen, P; Graff-Guerrero, A; Iwata, Y; Mihashi, Y; Mulsant, B; Nakajima, S; Plitman, E; Remington, G; Takeuchi, H, 2015) |
| "We aimed to assess the efficacy and tolerability of riluzole, an anti-glutamate agent with neuroprotective properties, as an adjunct to risperidone in improving negative symptoms of schizophrenia." | 5.19 | A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia. ( Akhondzadeh, S; Farokhnia, M; Hosseini, SM; Khodaie-Ardakani, MR; Pourmahmoud, H; Rezaei, F; Sabzabadi, M; Salehi, B; Tabrizi, M; Yekehtaz, H, 2014) |
| "A long-term randomized trial of unstable patients with schizophrenia found no benefit of long-acting injectable (LAI) risperidone over oral treatment in preventing or delaying time to psychiatric hospitalizations or on clinical outcomes." | 5.19 | Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia. ( Krystal, JH; Leatherman, SM; Lew, RA; Liang, MH; Rosenheck, RA; Thwin, SS; Valley, D, 2014) |
| "The objective of this study was to assess the efficacy and tolerability of tropisetron add-on to risperidone on negative symptoms in patients with chronic stable schizophrenia." | 5.17 | A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghasemi, S; Hosseini, SM; Khodaie-Ardakani, MR; Mirshafiee, O; Modabbernia, A; Noroozian, M; Rezaei, F; Salehi, B; Tabrizi, M; Tajdini, M; Yekehtaz, H, 2013) |
| "In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms." | 5.16 | A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. ( Ahmadi-Abhari, SA; Akhondzadeh, S; Arbabi, M; Bagheri, M; Khalighi-Sigaroudi, F; Rezaei, F; Tabrizi, M, 2012) |
| "Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals." | 5.16 | Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. ( Butcher, B; Emmerson, B; Hustig, H; Jacobs, A; Lambert, T; Resseler, S, 2012) |
| "Galantamine, a reversible cholinesterase inhibitor with effects on nicotinic receptors, has shown mixed effects on cognitive impairments in patients with schizophrenia." | 5.15 | Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. ( Khan, A; Lindenmayer, JP, 2011) |
| "The plasma levels of ADA in patients with chronic schizophrenia who received clozapine were significantly higher than patients who received haloperidol." | 5.15 | Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. ( Akhondzadeh, S; Boroumand, MA; Ghaleiha, A; Honarbakhsh, N; Jafarinia, M; Raznahan, M; Rezaei, F; Tabrizi, M, 2011) |
| "Eighty hospitalized patients suffering from Schizophrenia or Schizoaffective disorder (male 54, female 26) were first treated with Haloperidol (N=60) or Fluphenazine (N=20), and then were switched to Risperidone." | 5.15 | First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients. ( Popović, I; Popović, V; Ravanić, D; Stanojević, A; Stojanović, M; Vladejić, S, 2011) |
| "The efficacy, safety and tolerability of ziprasidone versus the comparators olanzapine, risperidone or quetiapine were investigated in adult patients with chronic schizophrenia, schizoaffective and schizophreniform disorders, with lack of efficacy or intolerance to their previous antipsychotic treatment based on clinical judgement of the investigator." | 5.14 | Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial. ( Haug, HJ; Kolb, SA; Koponen, H; Lublin, H; Sigmundsson, T, 2009) |
| "Comparisons of diabetic potential, glucose related metabolic levels, and insulin resistance between olanzapine and risperidone have produced variable results in cross-sectional and epidemiologic studies." | 5.14 | Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Khan, A; Lindenmayer, JP; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2009) |
| "Hospitalized patients with chronic schizophrenia, most of whom had been treated with multiple antipsychotics in the past, were randomly assigned to treatment with a single antipsychotic, olanzapine or risperidone, for a period of 5 months." | 5.14 | Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study. ( Cornwell, J; Davis, JM; Hu, Q; Kelly, E; Lindenmayer, JP; Marcovina, S; Smith, RC; Vaidhyanathaswamy, S; Viviano, TF, 2010) |
| "The role of partial agonism at 5-HT1A receptors in general and of buspirone in particular remains unclear in the treatment of negative symptoms of schizophrenia." | 5.14 | A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. ( Akhondzadeh, S; Farnaghi, F; Ghaleiha, A; Hajiazim, M; Noorbala, AA, 2010) |
| " All 200 patients who met the DSM-IV diagnostic criteria for schizophrenia were randomly assigned to double-blind treatment with WSKY capsule (n = 100) or placebo (n = 100) added on risperidone for 8 weeks." | 5.13 | Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial. ( Chen, RY; Chen, ZH; Huo, YX; Mei, HB; Wang, GH; Wang, HL; Wang, XP; Yang, MH, 2008) |
| "It has been reported that selegiline, a Selective Monoamine Oxidase Inhibitor B (MAOI-B), at low doses would be helpful for treating negative symptoms in schizophrenia." | 5.13 | Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. ( Akhondzadeh, S; Amiri, A; Derakhshan, MK; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Nejatisafa, AA; Noorbala, AA; Raznahan, M, 2008) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 5.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| "Among patients with chronic schizophrenia who avoid use of illicit drugs, olanzapine was more effective than other antipsychotics as reflected by longer time to all-cause discontinuation, but illicit substance abuse attenuated this advantage, reinforcing the need for concurrent substance abuse treatment." | 5.13 | The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. ( Canive, JM; Davis, SM; Hsiao, JK; Khan, A; Lieberman, JA; McEvoy, JP; McGee, M; Miller, DD; Reimherr, F; Stroup, TS; Swanson, JW; Swartz, MS; Wagner, HR, 2008) |
| "When a schizophrenia patient has an inadequate response to treatment with an antipsychotic drug, it is unclear what other antipsychotic to switch to and when to use clozapine." | 5.12 | Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Meltzer, HY; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| "Among this group of patients with chronic schizophrenia who had just discontinued treatment with an atypical antipsychotic, risperidone and olanzapine were more effective than quetiapine and ziprasidone as reflected by longer time until discontinuation for any reason." | 5.12 | Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. ( Davis, CE; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Perkins, DO; Rosenheck, RA; Severe, J; Stroup, TS; Swartz, MS, 2006) |
| " Data were pooled from four double-blind active comparator-controlled clinical trials involving 757 patients with schizophrenia treated for up to 8 weeks with either risperidone (4-6 mg/day) or a conventional antipsychotic such as haloperidol (10 or 20 mg/day), perphenazine (mean dose 28 mg/day), or zuclopenthixol (mean dose 38 mg/day)." | 5.12 | Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia. ( Glick, ID; Schreiner, A; Shkedy, Z, 2006) |
| "Subjects with schizophrenia (N=114) who had been randomly assigned to and then discontinued perphenazine in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia study were reassigned randomly to double-blinded treatment with olanzapine, 7." | 5.12 | Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. ( Belz, I; Capuano, GA; Davis, SM; Hsiao, JK; Keefe, RS; Lieberman, JA; McEvoy, JP; Miller, AL; Rosenheck, RA; Stroup, TS; Swartz, MS, 2007) |
| "To evaluate the clinical efficacy of modified Daotan Decoction (DD) combining low dosage of risperidone in treating chronic schizophrenia patients of phlegm-dampness blockage type, and compare with patients treated with risperidone alone." | 5.12 | [Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia]. ( Liu, JL; Ma, L; Wang, Y, 2007) |
| "Treatment outcome was evaluated in outpatients with chronic schizophrenia during long-term administration of risperidone in a study reflecting clinical practice." | 5.11 | Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone. ( Libretto, SE; Reveley, MA, 2004) |
| "This 14-week, multicenter, open-label, rater-blinded, randomized study evaluated the effects of a group-based behavioral treatment (BT) for weight loss in overweight and obese stable patients with DSM-IV schizophrenia or schizoaffective disorder who had been switched from olanzapine to risperidone." | 5.11 | Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. ( Berry, S; Brar, JS; Ganguli, R; Mahmoud, R; Pandina, G; Turkoz, I, 2005) |
| "We investigated the efficacy and safety of augmenting risperidone with fluvoxamine for the treatment of residual positive and negative symptoms in patients with chronic schizophrenia who had shown an incomplete response to risperidone." | 5.10 | Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial. ( Higuchi, H; Shimizu, T; Sugita, T; Takahashi, H, 2002) |
| "This multicenter, double-blind, randomized study evaluated the efficacy, safety and functional effects of two atypical antipsychotics, amisulpride and risperidone, in patients with chronic schizophrenia (DSM IV) with a recent worsening of symptoms." | 5.10 | Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. ( Fleurot, O; Lecrubier, Y; Peuskens, J; Rein, W; Sechter, D, 2002) |
| " typical (haloperidol) antipsychotic medication on facial emotion perception in schizophrenia (n=28) and healthy control (n=28) groups." | 5.10 | Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol. ( Gordon, E; Green, MJ; Harris, AW; Loughland, CM; Williams, LM, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "Clozapine and risperidone were the first two "second-generation" antipsychotic drugs approved for schizophrenia." | 5.09 | Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. ( Adler, CM; Breier, AF; Clifton, A; Elman, I; Lafargue, RT; Malhotra, AK; Pickar, D; Pinals, DA; Su, TP, 1999) |
| "There is little information regarding the effects of risperidone addition to neuroleptic treatment in chronic schizophrenia." | 5.09 | Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia. ( Oga, T; Okada, M; Takahashi, N; Terao, T, 1999) |
| "This study compared the long-term (12 months) effectiveness of risperidone (RP) with that of conventional neuroleptics (CNs) in a population with chronic schizophrenia who had shown suboptimal response to CNs." | 5.09 | Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group. ( Bouchard, RH; Cliche, D; Demers, MF; Filteau, MJ; Gauthier, Y; Labelle, A; Maziade, M; Mérette, C; Pourcher, E; Roy, MA; Roy-Gagnon, MH; Villeneuve, J, 2000) |
| "Studies have shown that risperidone is safe and efficacious in young and middle-aged adults with chronic schizophrenia, but considerably fewer data are available on the treatment of elderly patients with schizophrenia or other psychotic disorders, particularly long-term outcomes." | 5.09 | A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group. ( Barak, Y; Bray, G; Davidson, M; De Hooge, JD; Dose, M; Gagiano, CA; Harvey, PD; Haushofer, M; Vervarcke, J, 2000) |
| "During an 8-week period, 227 patients with DSM-III chronic schizophrenia received 4 mg/day of risperidone and 226 patients received 10 mg/day of haloperidol." | 5.09 | Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. ( Davidson, M; Hornik, T; Rabinowitz, J, 2001) |
| "This prospective, double-blind, multicenter, parallel-group study compared the efficacy and safety of therapeutic doses of clozapine and risperidone in patients with severe chronic schizophrenia and poor previous treatment response." | 5.09 | A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. ( Azorin, JM; Bourdeix, I; Giguere, M; Péré, JJ; Remington, G; Spiegel, R; Vanelle, JM, 2001) |
| "Given the renewed interest in the role of sex differences in schizophrenia, we undertook a post hoc analysis to determine whether sex differences in treatment response were present among outpatients with schizophrenia who received risperidone in an 8-week, open-label, Phase IV clinical study." | 5.09 | Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response. ( Dunbar, F; Labelle, A; Light, M, 2001) |
| "The hypothesis that differences in drug effects of risperidone and haloperidol on negative symptoms in schizophrenia are secondary to effects on positive, extrapyramidal, and depressive symptoms was investigated by means of an analysis of the data from the USA-Canada risperidone double-blind randomized clinical trial of 523 chronic schizophrenic patients." | 5.08 | A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. ( Borison, RL; Chouinard, G; Möller, HJ; Müller, H; Schooler, NR, 1995) |
| "In a multi-national, parallel-group, double-blind study, patients with chronic schizophrenia (DSM-III-R) were randomly assigned to risperidone 1, 4, 8, 12 or 16 mg or haloperidol 10 mg daily for 8 weeks." | 5.08 | Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. ( Peuskens, J, 1995) |
| "Risperidone was used to treat 11 elderly hospitalized patients between 61 and 79 years of age who manifested signs of psychoses related to schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia." | 5.08 | Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. ( Abaza, A; Araujo, L; Brenner, R; Madhusoodanan, S, 1995) |
| "Although risperidone has been shown to be an effective antipsychotic medication in schizophrenia, the clinical studies performed for the Food and Drug Administration's approval process focused on only a mixed group of schizophrenic patients." | 5.08 | Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study. ( Bhattacharyya, A; Chua, JW; Lipetsker, B; Smith, RC, 1996) |
| "The current study uses utility analysis to assess economic and quality-of-life benefits of risperidone in patients with chronic schizophrenia." | 5.08 | Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. ( Albright, PS; Chouinard, G, 1997) |
| " Patients with chronic schizophrenia were treated with risperidone at 1 mg/day (n = 25), 4 mg/day (n = 27), 8 mg/day (n = 29), 12 mg/day (n = 31), or 16 mg/day (n = 29), or 10 mg/day of haloperidol for 8 weeks." | 5.08 | Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. ( Bäuml, J; Ferrero, F; Fuger, J; Geretsegger, C; Kasper, S; Kissling, W; Möller, HJ; Schubert, H, 1997) |
| "In a controlled double-blind, multicenter study, 86 inpatients with chronic schizophrenia (DSM-III-R), who were resistant to or intolerant of conventional neuroleptics, were randomly assigned to receive risperidone or clozapine for 8 weeks after a 7-day washout period." | 5.08 | Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. ( Baumann, P; Billeter, U; Bondolfi, G; Dufour, H; Eap, CB; May, JP; Patris, M, 1998) |
| "Risperidone is a novel serotonin-dopamine antagonist antipsychotic in a class of benzisoxazole derivative which has been shown to be effective in reducing psychotic symptoms in schizophrenia." | 5.08 | Efficacy and tolerability of risperidone in chronic schizophrenic Thai patients. ( Bunditchate, A; Chaisirikul, S; Charisilp, C; Chrujiporn, W; Kessawai, D; Ratanachata, N; Sanichwannakul, K; Ukranand, P; Visanuyothin, T; Wangdee, P; Werapongset, W, 1998) |
| "Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia." | 5.08 | Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group. ( Beauclair, L; Chouinard, G; Johnson, SV; Kopala, L; Labelle, A; Singh, KI, 1998) |
| "In a double-blind study, 135 inpatients with a diagnosis of chronic schizophrenia were randomly assigned to 8 weeks of treatment with one of six parallel treatments: risperidone (a new central 5-hydroxytryptamine2 and dopamine D2 antagonist), 2, 6, 10, 16 mg/day; haloperidol, 20 mg/day; or placebo, after a single-blind placebo washout period." | 5.07 | A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. ( Addington, D; Arnott, W; Beauclair, L; Bloom, D; Chouinard, G; Jones, B; Labelle, A; MacEwan, GW; Remington, G, 1993) |
| "This multicenter trial indicates that risperidone is an effective treatment for the positive and negative symptoms of schizophrenia." | 5.07 | Risperidone: clinical development: north American results. ( Marder, SR, 1992) |
| "The unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the US Food and Drug Administration for treatment of refractory schizophrenia." | 4.79 | New antipsychotic medications: strategies for evaluation and selected findings. ( Schooler, NR, 1997) |
| " This study sought to explore the characteristics of white matter structural networks in chronic never-treated schizophrenia and those treated with clozapine or risperidone, and its potential association with cognitive function." | 3.96 | Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated. ( Gong, Q; Hu, N; Lencer, R; Li, S; Lui, S; Luo, C; Xiao, Y; Zhang, W, 2020) |
| "We used the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) to assess the cognition of three groups of schizophrenia patients (318 on clozapine, 125 on risperidone, and 166 on typical antipsychotic drugs) and 399 healthy controls, and used the Positive and Negative Syndrome Scale to assess schizophrenia symptoms of patients." | 3.96 | Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia. ( Dillon, BA; Dong, R; Du, XD; Jia, Q; Yang, Y; Yu, L; Yuan, L; Zhang, XY, 2020) |
| "To determine the cost-effectiveness of PP3M compared with once-monthly paliperidone (PP1M), haloperidol long-acting therapy (HAL-LAT), risperidone microspheres (RIS-LAT), and oral olanzapine (oral-OLZ) for treating chronic schizophrenia in The Netherlands." | 3.85 | Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. ( Bereza, BG; Denee, TR; Dries, PJT; Einarson, TR; Tedouri, F; Van Impe, K, 2017) |
| "To determine the cost-effectiveness of aripiprazole (ARI-LAI), paliperidone (PP-LAI), olanzapine (OLZ-LAI), and risperidone (RIS-LAI) in patients with chronic schizophrenia in Finland." | 3.83 | Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. ( Bereza, BG; Einarson, TR; Goswami, P; Pudas, H; van Impe, K, 2016) |
| " risperidone long acting injectable (RLAI), paliperidone long acting injectable (PLAI) and olanzapine long acting injectable (OLAI) in the maintenance treatment of chronic, stable schizophrenia patients in the United Kingdom." | 3.81 | Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK. ( Beillat, M; Robinson, P; Sapin, C; Tempest, M; Treur, M, 2015) |
| " The aim of this work was designed to investigate the diagnostic possibility of [(123)I]epidepride imaging platform for risperidone-treatment chronic MK-801-induced rat schizophrenia model." | 3.80 | Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging. ( Chang, KW; Chen, MW; Cheng, KH; Huang, YR; Kuo, WI; Pai, CW, 2014) |
| "To evaluate the efficacy and tolerability of long-acting risperidone injection in Thai patients with chronic schizophrenia for 12 weeks treatment." | 3.76 | Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. ( Arunpongpaisal, S; Kitiwattanagul, K; Kongsakon, R; Samanwongthai, U; Srisurapanont, M, 2010) |
| "A 31-year-old patient suffering from schizophrenic psychosis was treated with risperidone, and developed priapism which required surgical intervention and resulted in long-term erectile dysfunction." | 3.74 | Risperidone-induced priapism. ( Makesar, D; Thome, J, 2007) |
| "We identified patients with schizophrenia from outpatient clinics in the Veterans Health Administration (VA) and defined initiation of olanzapine or risperidone as patients who were not on any antipsychotics for 6 months and subsequently initiated on the target drug between 1/4/1999 and 31/3/2000." | 3.73 | Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. ( Huang, YH; Kazis, L; Lee, AF; Miller, DR; Qian, S; Ren, XS, 2005) |
| "We studied a sample of schizophrenia out-patients to test the hypotheses that serum homocysteine concentrations would correlate positively with measures of glucose metabolism." | 3.73 | Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia. ( Baer, L; Borba, CP; Cather, C; Copeland, PM; Eden Evins, A; Freudenreich, O; Goff, DC; Henderson, DC; Nguyen, DD, 2006) |
| "Risperidone, olanzapine, and clozapine are three atypical antipsychotic medications commonly used in the management of chronic schizophrenia." | 3.73 | Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study. ( Gonen, N; Kupchik, M; Mester, R; Roitman, S; Schwartz, S; Spivak, B; Strous, RD; Weizman, A, 2006) |
| "The effect of mirtazapine on steady-state plasma concentrations of the newer atypical antipsychotics clozapine, risperidone and olanzapine was investigated in 24 patients with chronic schizophrenia." | 3.72 | Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia. ( Canale, A; Crucitti, D; D'Arrigo, C; Malara, G; Muscatello, MR; Spina, E; Torre, DL; Zoccali, R, 2003) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "Priapism has been associated with many antipsychotic agents, including clozapine, risperidone, and olanzapine." | 3.71 | Priapism associated with two atypical antipsychotic agents. ( Mack, JE; Reeves, RR, 2002) |
| "By using Israel's National Psychiatric Hospitalization Case Registry, rehospitalization status was monitored for all patients with schizophrenia who were discharged from any inpatient psychiatric facility in Israel while taking risperidone (N=268) or olanzapine (N=313) between Jan." | 3.71 | Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. ( Davidson, M; Kaplan, Z; Lichtenberg, P; Mark, M; Nahon, D; Rabinowitz, J, 2001) |
| " The patient had long-standing schizophrenia and had been taking risperidone for 2 years, without evidence of abnormal movements." | 3.71 | Hyperthermia and chronic pancerebellar syndrome after cocaine abuse. ( Dissin, J; Selcer, UM; Tanvetyanon, T, 2001) |
| "Several years ago, we reported that the addition of risperidone to clozapine improved response in some patients with schizophrenia." | 3.71 | Risperidone added to clozapine: impact on serum prolactin levels. ( Borba, CP; Connolly, CE; Goff, DC; Hayden, D; Henderson, DC, 2001) |
| "Clozapine was reserved for more severe forms of schizophrenia, but its cost impact was relatively low." | 3.71 | Service use and costs of treating schizophrenia with atypical antipsychotics. ( Frangou, S; Lewis, M; McCrone, P, 2001) |
| "An open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia." | 3.70 | Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. ( Addington, DE; Gagiano, CA; Gaussares, C; Möller, HJ; Torres-Plank, JF; Von Knorring, L, 1998) |
| "Patients displaying a moderate-to-marked response to risperidone were more likely to be younger; receive diagnoses of bipolar disorder or schizoaffective disorder, depressive type; and have a shorter duration of illness and shorter length of stay prior to risperidone treatment." | 3.69 | Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. ( Balistreri, TM; DePriest, M; Holtman, HM; Keck, PE; Kizer, DL; McElroy, SL; Strakowski, SM; Wilson, DR, 1995) |
| "To determine whether or not risperidone is efficacious in treating self-induced water intoxication in patients with chronic schizophrenia." | 3.69 | Self-induced water intoxication treated with risperidone. ( Emes, CE; Glackman, WG; Millson, RC, 1996) |
| "A prospective, open-label study in a 400-bed state psychiatric hospital evaluated change in therapeutic response among ten patients with treatment-resistant schizophrenia who were switched from clozapine to risperidone." | 3.69 | Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. ( Crismon, ML; Dorson, PG; Pousson, C; Still, DJ, 1996) |
| "The effects of risperidone treatment on health care utilization and treatment costs were examined among patients with treatment-refractory schizophrenia or schizoaffective disorder." | 3.69 | Impact of risperidone on the use of mental health care resources. ( Durkin, M; Engelhart, L; Lawrence, BJ; Maislin, G; Mechling, L; Viale, G, 1997) |
| " Most frequently reported treatment-related adverse events (ie, ≥5% of patients in either TV-46000 group) that occurred more often in patients receiving TV-46000 (once monthly or once every 2 months) versus placebo were injection site nodules (7% for TV-46000 once monthly, 7% for TV-46000 once every 2 months, 3% for placebo), weight increased (4%, 6%, 2%, respectively), and extrapyramidal disorder (5%, 3%, 0% respectively)." | 3.30 | Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria. ( Correll, CU; Davis, GL; Eshet, R; Franzenburg, KR; Harary, E; Kane, JM; Leucht, S; Merenlender-Wagner, A; Sharon, N; Suett, M; Tohami, O; Weiser, M, 2023) |
| "Perphenazine was noninferior to all three SGAs during 18 months of intention-to-treat analysis and in several subanalyses." | 2.79 | Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia. ( Lin, H; Rosenheck, R, 2014) |
| "T-tests showed that the PTSD sample had more severe symptoms on the Depressive factor, and the schizophrenia sample on the Positive, Negative, and Disorganized factors, with no significant difference on the Excited factor." | 2.79 | Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia. ( Krystal, JH; Rosenheck, RA; Stefanovics, EA, 2014) |
| "The Clinician-Administered PTSD Scale (CAPS) (range, 0-136)." | 2.76 | Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial. ( Cramer, JA; Horney, RA; Huang, GD; Jones, KM; Krystal, JH; Rosenheck, RA; Stock, C; Vertrees, JE; Vessicchio, JC, 2011) |
| "Propentofylline is a novel xantine derivative which is being developed for treatment of degenerative and vascular dementia." | 2.73 | A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. ( Abbasi, SH; Ahmadi-Abhari, SA; Akhondzadeh, S; Derakhshan, MK; Fotouhi, A; Ghoreishi, A; Hajiazim, M; Khodaie-Ardakani, MR; Mohammadi, MR; Noorbala, AA; Salimi, S, 2008) |
| "Only risperidone-treated patients exhibited significant decreases in uncontrolled hostility/excitement and anxiety and depression." | 2.72 | Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study. ( Borisov, A; Feldman, J; May, R; Miller, AH; Nemeroff, CB; Rosenberg, J; Savage, R; Tucker, M; Wang, X; Woolwine, B, 2006) |
| "Evaluation of relationships between serum antipsychotic drug concentrations and clinical response may provide valuable information for rational dosage adjustments." | 2.70 | Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. ( Ancione, M; Avenoso, A; Facciolà, G; Madia, AG; Perucca, E; Salemi, M; Scordo, MG; Spina, E, 2001) |
| "Risperidone appears to be a more effective and better tolerated antipsychotic drug in treatment-refractory Chinese schizophrenia than haloperidol." | 2.70 | Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. ( Cao, LY; Shen, YC; Wu, GY; Zhang, PY; Zhang, XY; Zhou, DF, 2001) |
| "Risperidone treatment significantly increased the serum PRL levels of schizophrenic patients." | 2.70 | Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. ( Shen, YC; Wu, GY; Yuan, CL; Zhang, PY; Zhang, XY; Zhou, DF, 2002) |
| " Following are the mean pharmacokinetics of risperidone and risperidone + 9-OH-risperidone: area under the plasma concentration curve (AUC) from 0 to 96 hours; 278." | 2.67 | Pharmacokinetics of risperidone in chronic schizophrenic patients. ( Borison, RL; Diamond, B; Meibach, RC; Pathiraja, A, 1994) |
| " Safety was monitored by open adverse event reporting, the Simpson-Angus Scale, the Barnes Akathisia Scale and the Abnormal Involuntary Movement scale." | 2.41 | Safety profile of amisulpride in short- and long-term use. ( Coulouvrat, C; Dondey-Nouvel, L; Rein, W, 2000) |
| "Treating schizophrenia is costly for health systems." | 1.43 | Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. ( Bereza, BG; Einarson, TR; Goswami, P; Maia-Lopes, S; Van Impe, K, 2016) |
| " Chronic administration of RPD or HPD had no significant effect on (13)C-PBT indices in rats." | 1.38 | 13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients. ( Chiba, S; Hattori, K; Higuchi, T; Hori, H; Iijima, Y; Kajiwara, M; Kawamoto, Y; Kinoshita, Y; Kunugi, H; Matsuo, J; Ota, M; Ozeki, Y; Sasayama, D; Tanaka, H; Terada, S; Teraishi, T; Yamamoto, N, 2012) |
| "Risperidone pretreatment significantly attenuated increases in the levels of DA, 5-HT, glutamate, and NOx." | 1.36 | Effect of risperidone on acute methamphetamine-induced hyperthermia in rats. ( Kato, S; Nisijima, K; Shioda, K; Yoshino, T, 2010) |
| " Side effects were carefully monitored using adverse event evaluation charts." | 1.33 | Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. ( Cho, SC; Hwang, JW; Kim, BN; Lee, CB; Shin, MS, 2005) |
| " Failure in switching to monotherapy was associated with higher dosage of antipsychotics at baseline." | 1.33 | Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia. ( Kunugi, H; Murray, RM; Nakanishi, S; Nojima, S; Ogawa, T; Takahashi, T, 2006) |
| "96 SD were treated with risperidone (RSP) at the dosage of 2-9 mg/die (mean 4." | 1.31 | Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels. ( Boscati, L; Laini, V; Mauri, MC; Orlandi, R; Papa, P; Rudelli, R; Salvi, V, 2001) |
| "The sample included five patients with Tourette's syndrome and two with chronic motor tic disorder." | 1.29 | Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. ( Chappell, PB; King, RA; Leckman, JF; Lombroso, PJ; Lynch, KA; McDougle, CJ; Peterson, BS; Scahill, L, 1995) |
| "Risperidone appears to be an effective and well tolerated antipsychotic for elderly patients with chronic psychosis." | 1.29 | Outcome of risperidone therapy in elderly patients with chronic psychosis. ( Brescan, D; Jurjus, G; Ramirez, LF; Sajatovic, M; Simon, M; Vernon, L, 1996) |
| "Risperidone is a new benzisoxazole derivative displaying a very potent serotonin antagonism and a potent dopamine antagonism in pharmacological studies." | 1.28 | Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study. ( Kissling, W; Möller, HJ; Pelzer, E; Riehl, T; Wernicke, T, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 47 (27.49) | 18.2507 |
| 2000's | 84 (49.12) | 29.6817 |
| 2010's | 36 (21.05) | 24.3611 |
| 2020's | 4 (2.34) | 2.80 |
| Authors | Studies |
|---|---|
| Kane, JM | 3 |
| Harary, E | 1 |
| Eshet, R | 1 |
| Tohami, O | 1 |
| Weiser, M | 1 |
| Leucht, S | 1 |
| Merenlender-Wagner, A | 1 |
| Sharon, N | 1 |
| Davis, GL | 1 |
| Suett, M | 1 |
| Franzenburg, KR | 1 |
| Correll, CU | 1 |
| Schaefer, M | 1 |
| Sarkar, S | 1 |
| Theophil, I | 1 |
| Leopold, K | 1 |
| Heinz, A | 1 |
| Gallinat, J | 1 |
| Luo, C | 1 |
| Lencer, R | 1 |
| Hu, N | 1 |
| Xiao, Y | 1 |
| Zhang, W | 1 |
| Li, S | 1 |
| Lui, S | 1 |
| Gong, Q | 1 |
| Dong, R | 1 |
| Yuan, L | 1 |
| Yang, Y | 1 |
| Du, XD | 1 |
| Jia, Q | 1 |
| Dillon, BA | 1 |
| Yu, L | 1 |
| Zhang, XY | 5 |
| Einarson, TR | 5 |
| Bereza, BG | 3 |
| Tedouri, F | 1 |
| Van Impe, K | 3 |
| Denee, TR | 1 |
| Dries, PJT | 1 |
| Noroozian, M | 3 |
| Ghasemi, S | 1 |
| Hosseini, SM | 2 |
| Modabbernia, A | 1 |
| Khodaie-Ardakani, MR | 5 |
| Mirshafiee, O | 1 |
| Farokhnia, M | 4 |
| Tajdini, M | 1 |
| Rezaei, F | 6 |
| Salehi, B | 3 |
| Ashrafi, M | 1 |
| Yekehtaz, H | 3 |
| Tabrizi, M | 5 |
| Akhondzadeh, S | 13 |
| Zilbershtein, R | 2 |
| Skoupá, J | 1 |
| Veselá, S | 1 |
| Garg, M | 1 |
| Hemels, ME | 2 |
| Pudas, H | 2 |
| Jensen, R | 1 |
| Vicente, C | 1 |
| Piwko, C | 1 |
| Sabzabadi, M | 1 |
| Pourmahmoud, H | 1 |
| Leatherman, SM | 1 |
| Liang, MH | 1 |
| Krystal, JH | 3 |
| Lew, RA | 1 |
| Valley, D | 1 |
| Thwin, SS | 1 |
| Rosenheck, RA | 10 |
| Rosenheck, R | 1 |
| Lin, H | 2 |
| Stefanovics, EA | 1 |
| Huang, YR | 1 |
| Pai, CW | 1 |
| Cheng, KH | 1 |
| Kuo, WI | 1 |
| Chen, MW | 1 |
| Chang, KW | 1 |
| Kianimehr, G | 1 |
| Fatehi, F | 1 |
| Hashempoor, S | 1 |
| Khodaei-Ardakani, MR | 1 |
| Nazari, A | 1 |
| Kashani, L | 1 |
| Zeinoddini, A | 2 |
| Ahadi, M | 1 |
| Nakajima, S | 1 |
| Takeuchi, H | 1 |
| Fervaha, G | 1 |
| Plitman, E | 1 |
| Chung, JK | 1 |
| Caravaggio, F | 1 |
| Iwata, Y | 1 |
| Mihashi, Y | 1 |
| Gerretsen, P | 1 |
| Remington, G | 3 |
| Mulsant, B | 1 |
| Graff-Guerrero, A | 1 |
| Mohamed, S | 1 |
| Swartz, M | 1 |
| McEvoy, J | 1 |
| Stroup, S | 1 |
| Goswami, P | 2 |
| Tempest, M | 1 |
| Sapin, C | 1 |
| Beillat, M | 1 |
| Robinson, P | 1 |
| Treur, M | 1 |
| Iranpour, N | 1 |
| Zandifar, A | 1 |
| Goguol, A | 1 |
| Esalatmanesh, S | 1 |
| Zeionoddini, A | 1 |
| Mohammadinejad, P | 1 |
| Maia-Lopes, S | 1 |
| Benarous, X | 1 |
| Consoli, A | 1 |
| Guilé, JM | 1 |
| Garny de La Rivière, S | 1 |
| Cohen, D | 1 |
| Olliac, B | 1 |
| Chen, ZH | 1 |
| Wang, GH | 1 |
| Wang, XP | 1 |
| Chen, RY | 1 |
| Wang, HL | 1 |
| Yang, MH | 1 |
| Huo, YX | 1 |
| Mei, HB | 1 |
| Fusar-Poli, RR | 1 |
| Gerami, M | 1 |
| Karamghadiri, N | 2 |
| Ghoreishi, A | 4 |
| Abbasi, SH | 3 |
| Rezazadeh, SA | 1 |
| Mohammadi, N | 1 |
| Jamshidi, AH | 1 |
| Forghani, S | 1 |
| Lublin, H | 1 |
| Haug, HJ | 1 |
| Koponen, H | 1 |
| Sigmundsson, T | 1 |
| Kolb, SA | 1 |
| Vehof, J | 1 |
| Postma, MJ | 1 |
| Bruggeman, R | 1 |
| De Jong-Van Den Berg, LT | 1 |
| Van Den Berg, PB | 1 |
| Stolk, RP | 1 |
| Burger, H | 1 |
| Stroup, TS | 7 |
| Lieberman, JA | 8 |
| McEvoy, JP | 9 |
| Davis, SM | 7 |
| Swartz, MS | 7 |
| Keefe, RS | 6 |
| Miller, AL | 2 |
| Hsiao, JK | 7 |
| Zhou, DF | 4 |
| Qi, LY | 1 |
| Chen, S | 1 |
| Cao, LY | 3 |
| Chen, DC | 1 |
| Xiu, MH | 1 |
| Wang, F | 1 |
| Wu, GY | 4 |
| Lu, L | 1 |
| Kosten, TA | 2 |
| Kosten, TR | 2 |
| Smith, RC | 3 |
| Lindenmayer, JP | 5 |
| Davis, JM | 2 |
| Kelly, E | 2 |
| Viviano, TF | 2 |
| Cornwell, J | 2 |
| Hu, Q | 2 |
| Khan, A | 3 |
| Vaidhyanathaswamy, S | 2 |
| Sapunar Z, J | 1 |
| Muñoz N, S | 1 |
| Vásquez A, T | 1 |
| Girardi, P | 1 |
| Serafini, G | 1 |
| Pompili, M | 1 |
| Innamorati, M | 1 |
| Tatarelli, R | 1 |
| Baldessarini, RJ | 2 |
| Macfadden, W | 1 |
| Bossie, CA | 2 |
| Turkoz, I | 2 |
| Haskins, JT | 1 |
| Arunpongpaisal, S | 1 |
| Srisurapanont, M | 1 |
| Kongsakon, R | 1 |
| Kitiwattanagul, K | 1 |
| Samanwongthai, U | 1 |
| Marcovina, S | 1 |
| Shioda, K | 1 |
| Nisijima, K | 1 |
| Yoshino, T | 1 |
| Kato, S | 1 |
| Marston, HM | 1 |
| Martin, FD | 1 |
| Papp, M | 1 |
| Gold, L | 1 |
| Wong, EH | 1 |
| Shahid, M | 1 |
| Ghaleiha, A | 2 |
| Noorbala, AA | 3 |
| Farnaghi, F | 1 |
| Hajiazim, M | 3 |
| McNamara, RK | 1 |
| Jandacek, R | 1 |
| Rider, T | 1 |
| Tso, P | 1 |
| Honarbakhsh, N | 1 |
| Boroumand, MA | 1 |
| Jafarinia, M | 1 |
| Raznahan, M | 2 |
| Chou, PH | 1 |
| Lin, BT | 1 |
| Lan, TH | 1 |
| Chan, CH | 1 |
| Cramer, JA | 1 |
| Vessicchio, JC | 1 |
| Jones, KM | 1 |
| Vertrees, JE | 1 |
| Horney, RA | 1 |
| Huang, GD | 1 |
| Stock, C | 1 |
| Arbabi, M | 1 |
| Bagheri, M | 1 |
| Ahmadi-Abhari, SA | 2 |
| Khalighi-Sigaroudi, F | 1 |
| Popović, I | 1 |
| Ravanić, D | 1 |
| Popović, V | 1 |
| Vladejić, S | 1 |
| Stanojević, A | 1 |
| Stojanović, M | 1 |
| Lambert, T | 1 |
| Emmerson, B | 1 |
| Hustig, H | 1 |
| Resseler, S | 1 |
| Jacobs, A | 1 |
| Butcher, B | 1 |
| Howland, RH | 1 |
| Teraishi, T | 1 |
| Ozeki, Y | 1 |
| Hori, H | 1 |
| Sasayama, D | 1 |
| Chiba, S | 1 |
| Yamamoto, N | 1 |
| Tanaka, H | 1 |
| Iijima, Y | 1 |
| Matsuo, J | 1 |
| Kawamoto, Y | 1 |
| Kinoshita, Y | 1 |
| Hattori, K | 1 |
| Ota, M | 1 |
| Kajiwara, M | 1 |
| Terada, S | 1 |
| Higuchi, T | 1 |
| Kunugi, H | 2 |
| Naber, D | 1 |
| Kollack-Walker, S | 1 |
| Chen, J | 1 |
| Stauffer, VL | 1 |
| Kinon, BJ | 1 |
| Case, M | 1 |
| Ascher-Svanum, H | 1 |
| Kapur, S | 1 |
| Reeves, RR | 1 |
| Mack, JE | 1 |
| Takahashi, H | 1 |
| Sugita, T | 1 |
| Higuchi, H | 1 |
| Shimizu, T | 1 |
| Sechter, D | 1 |
| Peuskens, J | 4 |
| Fleurot, O | 1 |
| Rein, W | 2 |
| Lecrubier, Y | 1 |
| Conlon, L | 1 |
| Fahy, TJ | 1 |
| OToole, R | 1 |
| Gilligan, J | 1 |
| Prescott, P | 1 |
| Molina, V | 3 |
| Gispert, JD | 2 |
| Reig, S | 3 |
| Sanz, J | 3 |
| Pascau, J | 3 |
| Santos, A | 1 |
| Palomo, T | 3 |
| Desco, M | 3 |
| Osser, DN | 1 |
| Akhter, A | 1 |
| Zoccali, R | 1 |
| Muscatello, MR | 1 |
| Torre, DL | 1 |
| Malara, G | 1 |
| Canale, A | 1 |
| Crucitti, D | 1 |
| D'Arrigo, C | 1 |
| Spina, E | 3 |
| Williams, LM | 1 |
| Loughland, CM | 1 |
| Green, MJ | 1 |
| Harris, AW | 1 |
| Gordon, E | 1 |
| Philipp, M | 2 |
| Lesch, OM | 2 |
| Schmauss, M | 2 |
| Dose, M | 2 |
| Glaser, T | 1 |
| Feldman, PD | 1 |
| Kaiser, CJ | 1 |
| Kennedy, JS | 1 |
| Sutton, VK | 1 |
| Tran, PV | 1 |
| Tollefson, GD | 1 |
| Zhang, F | 1 |
| Breier, A | 1 |
| Levy, E | 1 |
| Margolese, HC | 1 |
| Sultan, S | 1 |
| Chouinard, G | 5 |
| Pajonk, FG | 1 |
| Loh, C | 1 |
| Leckband, SG | 1 |
| Meyer, JM | 1 |
| Turner, E | 1 |
| Reveley, MA | 1 |
| Libretto, SE | 1 |
| Lemon, M | 1 |
| David, D | 2 |
| De Faria, L | 2 |
| Lapeyra, O | 1 |
| Mellman, TA | 2 |
| Listernick, R | 1 |
| Heveling, T | 1 |
| Emrich, HM | 1 |
| Dietrich, DE | 1 |
| Sánchez, J | 2 |
| Benito, C | 2 |
| Santamarta, C | 1 |
| Sarramea, F | 2 |
| Misiego, JM | 1 |
| Ren, XS | 1 |
| Huang, YH | 1 |
| Lee, AF | 1 |
| Miller, DR | 1 |
| Qian, S | 1 |
| Kazis, L | 1 |
| Brar, JS | 1 |
| Ganguli, R | 1 |
| Pandina, G | 1 |
| Berry, S | 1 |
| Mahmoud, R | 1 |
| Lasser, RA | 1 |
| Gharabawi, GM | 1 |
| Kim, BN | 1 |
| Lee, CB | 1 |
| Hwang, JW | 1 |
| Shin, MS | 1 |
| Cho, SC | 1 |
| Perkins, DO | 4 |
| Davis, CE | 3 |
| Lebowitz, BD | 1 |
| Severe, J | 3 |
| Henderson, DC | 3 |
| Copeland, PM | 1 |
| Nguyen, DD | 1 |
| Borba, CP | 2 |
| Cather, C | 1 |
| Eden Evins, A | 1 |
| Freudenreich, O | 1 |
| Baer, L | 1 |
| Goff, DC | 3 |
| Parak, M | 1 |
| Gorman, JM | 1 |
| Meltzer, HY | 1 |
| Wang, X | 1 |
| Savage, R | 1 |
| Borisov, A | 1 |
| Rosenberg, J | 1 |
| Woolwine, B | 1 |
| Tucker, M | 1 |
| May, R | 1 |
| Feldman, J | 1 |
| Nemeroff, CB | 1 |
| Miller, AH | 1 |
| Strous, RD | 1 |
| Kupchik, M | 1 |
| Roitman, S | 1 |
| Schwartz, S | 1 |
| Gonen, N | 1 |
| Mester, R | 1 |
| Weizman, A | 1 |
| Spivak, B | 1 |
| Glick, ID | 1 |
| Shkedy, Z | 1 |
| Schreiner, A | 1 |
| Baptista, T | 1 |
| Martinez, M | 1 |
| Lacruz, A | 1 |
| Arellano, A | 1 |
| Mendoza, S | 1 |
| Beaulieu, S | 1 |
| Hernández, L | 1 |
| Contreras, Q | 1 |
| Galeazzi, T | 1 |
| Vargas, D | 1 |
| Tan, YL | 1 |
| Xu, Q | 1 |
| Shen, Y | 1 |
| Haile, CN | 1 |
| Nakanishi, S | 1 |
| Murray, RM | 1 |
| Nojima, S | 1 |
| Ogawa, T | 1 |
| Takahashi, T | 1 |
| Tabatabaee, M | 1 |
| Amini, H | 1 |
| Ahmadi Abhari, SA | 1 |
| Behnam, B | 1 |
| Tanaka, Y | 1 |
| Yoshida, S | 1 |
| Shimada, Y | 1 |
| Ueda, H | 1 |
| Asai, K | 1 |
| Capuano, G | 1 |
| Reimherr, F | 2 |
| McGee, MF | 1 |
| Capuano, GA | 1 |
| Belz, I | 1 |
| Makesar, D | 1 |
| Thome, J | 1 |
| Ruhrmann, S | 1 |
| Kissling, W | 3 |
| Seemann, U | 1 |
| Liu, JL | 1 |
| Ma, L | 1 |
| Wang, Y | 1 |
| Silver, H | 1 |
| Goodman, C | 1 |
| Amiri, A | 1 |
| Nejatisafa, AA | 1 |
| Derakhshan, MK | 2 |
| Bratti, IM | 1 |
| Marder, SR | 2 |
| Perez-Iglesias, R | 1 |
| Crespo-Facorro, B | 1 |
| Martinez-Garcia, O | 1 |
| Ramirez-Bonilla, ML | 1 |
| Alvarez-Jimenez, M | 1 |
| Pelayo-Teran, JM | 1 |
| Garcia-Unzueta, MT | 1 |
| Amado, JA | 1 |
| Vazquez-Barquero, JL | 1 |
| Salimi, S | 1 |
| Fotouhi, A | 1 |
| Mohammadi, MR | 1 |
| Wagner, HR | 1 |
| Swanson, JW | 1 |
| Miller, DD | 1 |
| McGee, M | 1 |
| Canive, JM | 1 |
| Pary, R | 1 |
| Tobias, CR | 1 |
| Lippmann, S | 1 |
| Emes, CE | 2 |
| Millson, RC | 2 |
| Borison, RL | 2 |
| Diamond, B | 1 |
| Pathiraja, A | 1 |
| Meibach, RC | 1 |
| O'Croinin, F | 1 |
| Zibin, T | 1 |
| Holt, L | 1 |
| Möller, HJ | 5 |
| Müller, H | 1 |
| Schooler, NR | 2 |
| Lombroso, PJ | 1 |
| Scahill, L | 1 |
| King, RA | 1 |
| Lynch, KA | 1 |
| Chappell, PB | 1 |
| Peterson, BS | 1 |
| McDougle, CJ | 2 |
| Leckman, JF | 1 |
| Keck, PE | 1 |
| Wilson, DR | 1 |
| Strakowski, SM | 1 |
| McElroy, SL | 1 |
| Kizer, DL | 1 |
| Balistreri, TM | 1 |
| Holtman, HM | 1 |
| DePriest, M | 1 |
| Madhusoodanan, S | 1 |
| Brenner, R | 1 |
| Araujo, L | 1 |
| Abaza, A | 1 |
| Jones, B | 1 |
| Bloom, D | 1 |
| Addington, D | 1 |
| MacEwan, GW | 1 |
| Labelle, A | 4 |
| Beauclair, L | 2 |
| Arnott, W | 1 |
| Min, SK | 1 |
| Rhee, CS | 1 |
| Kim, CE | 1 |
| Kang, DY | 1 |
| Avnon, M | 1 |
| Kunin, A | 1 |
| Bazire, S | 1 |
| Negrón, AE | 1 |
| Leiderman, EA | 1 |
| Parkadavil, M | 1 |
| Cienfuegos, A | 1 |
| Javitt, DC | 1 |
| Chua, JW | 1 |
| Lipetsker, B | 1 |
| Bhattacharyya, A | 1 |
| Sajatovic, M | 1 |
| Ramirez, LF | 1 |
| Vernon, L | 1 |
| Brescan, D | 1 |
| Simon, M | 1 |
| Jurjus, G | 1 |
| Glackman, WG | 1 |
| Kopala, LC | 1 |
| Patel, JK | 1 |
| Salzman, C | 1 |
| Green, AI | 1 |
| Tsuang, MT | 1 |
| Still, DJ | 1 |
| Dorson, PG | 1 |
| Crismon, ML | 1 |
| Pousson, C | 1 |
| Albright, PS | 1 |
| Viale, G | 1 |
| Mechling, L | 1 |
| Maislin, G | 1 |
| Durkin, M | 1 |
| Engelhart, L | 1 |
| Lawrence, BJ | 1 |
| Kern, RS | 1 |
| Marshall, BD | 1 |
| Kuehnel, TG | 1 |
| Mintz, J | 1 |
| Hayden, JL | 1 |
| Robertson, MJ | 1 |
| Green, MF | 1 |
| Bäuml, J | 1 |
| Ferrero, F | 1 |
| Fuger, J | 1 |
| Geretsegger, C | 1 |
| Kasper, S | 1 |
| Schubert, H | 1 |
| Lane, HY | 2 |
| Lin, YC | 1 |
| Chang, WH | 2 |
| Bondolfi, G | 1 |
| Dufour, H | 1 |
| Patris, M | 1 |
| May, JP | 1 |
| Billeter, U | 1 |
| Eap, CB | 1 |
| Baumann, P | 1 |
| Werapongset, W | 1 |
| Chaisirikul, S | 1 |
| Chrujiporn, W | 1 |
| Visanuyothin, T | 1 |
| Kessawai, D | 1 |
| Charisilp, C | 1 |
| Ratanachata, N | 1 |
| Sanichwannakul, K | 1 |
| Wangdee, P | 1 |
| Bunditchate, A | 1 |
| Ukranand, P | 1 |
| Gagiano, CA | 2 |
| Addington, DE | 1 |
| Von Knorring, L | 2 |
| Torres-Plank, JF | 1 |
| Gaussares, C | 1 |
| Shiwach, RS | 1 |
| Carmody, TJ | 1 |
| Kopala, L | 1 |
| Johnson, SV | 1 |
| Singh, KI | 1 |
| Moore, DB | 1 |
| Kelly, DL | 1 |
| Sherr, JD | 1 |
| Love, RC | 1 |
| Conley, RR | 1 |
| Breier, AF | 1 |
| Malhotra, AK | 1 |
| Su, TP | 1 |
| Pinals, DA | 1 |
| Elman, I | 1 |
| Adler, CM | 1 |
| Lafargue, RT | 1 |
| Clifton, A | 1 |
| Pickar, D | 1 |
| Takahashi, N | 1 |
| Terao, T | 1 |
| Oga, T | 1 |
| Okada, M | 1 |
| Epperson, CN | 1 |
| Fasula, D | 1 |
| Wasylink, S | 1 |
| Price, LH | 1 |
| See, RE | 1 |
| Fido, AA | 1 |
| Maurice, M | 1 |
| Ibrahim, MM | 1 |
| Salama, GM | 1 |
| Megna, JL | 1 |
| Dewan, M | 1 |
| Ende, G | 1 |
| Braus, DF | 1 |
| Walter, S | 1 |
| Weber-Fahr, W | 1 |
| Soher, B | 1 |
| Maudsley, AA | 1 |
| Henn, FA | 1 |
| Coulouvrat, C | 1 |
| Dondey-Nouvel, L | 1 |
| Bouchard, RH | 1 |
| Mérette, C | 1 |
| Pourcher, E | 1 |
| Demers, MF | 1 |
| Villeneuve, J | 1 |
| Roy-Gagnon, MH | 1 |
| Gauthier, Y | 1 |
| Cliche, D | 1 |
| Filteau, MJ | 1 |
| Roy, MA | 1 |
| Maziade, M | 1 |
| Davidson, M | 4 |
| Harvey, PD | 1 |
| Vervarcke, J | 1 |
| De Hooge, JD | 1 |
| Bray, G | 1 |
| Barak, Y | 2 |
| Haushofer, M | 1 |
| Azhar, MZ | 1 |
| Rabinowitz, J | 3 |
| Lichtenberg, P | 1 |
| Kaplan, Z | 1 |
| Mark, M | 1 |
| Nahon, D | 1 |
| Scordo, MG | 2 |
| Avenoso, A | 2 |
| Perucca, E | 2 |
| Facciolà, G | 1 |
| Salemi, M | 1 |
| Ancione, M | 1 |
| Madia, AG | 1 |
| Chue, P | 1 |
| Welch, R | 1 |
| Snaterse, M | 1 |
| Mauri, MC | 1 |
| Laini, V | 1 |
| Boscati, L | 1 |
| Rudelli, R | 1 |
| Salvi, V | 1 |
| Orlandi, R | 1 |
| Papa, P | 1 |
| de Groot, IW | 1 |
| Heck, AH | 1 |
| van Harten, PN | 1 |
| Tanvetyanon, T | 1 |
| Dissin, J | 1 |
| Selcer, UM | 1 |
| Cuesta, MJ | 1 |
| Peralta, V | 1 |
| Zarzuela, A | 1 |
| Hornik, T | 1 |
| Azorin, JM | 1 |
| Spiegel, R | 1 |
| Vanelle, JM | 1 |
| Péré, JJ | 1 |
| Giguere, M | 1 |
| Bourdeix, I | 1 |
| Light, M | 1 |
| Dunbar, F | 1 |
| Connolly, CE | 1 |
| Hayden, D | 1 |
| Zhang, PY | 2 |
| Shen, YC | 2 |
| Lewis, M | 1 |
| McCrone, P | 1 |
| Frangou, S | 1 |
| Volavka, J | 1 |
| Czobor, P | 1 |
| Sheitman, B | 1 |
| Citrome, L | 1 |
| Cooper, TB | 1 |
| Chakos, M | 1 |
| Shamir, E | 1 |
| Weizman, R | 1 |
| Yuan, CL | 1 |
| Lindström, E | 1 |
| Claus, A | 2 |
| Bollen, J | 2 |
| De Cuyper, H | 2 |
| Eneman, M | 2 |
| Malfroid, M | 2 |
| Heylen, S | 2 |
| Wilms, G | 1 |
| Van Ongeval, C | 1 |
| Baert, AL | 1 |
| Pelzer, E | 1 |
| Riehl, T | 1 |
| Wernicke, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Acute Schizophrenia: Results of a Proof of Concept Study[NCT00148590] | Phase 3 | 24 participants (Actual) | Interventional | 2005-11-30 | Terminated | ||
| Memantine add-on to Risperidon for Treatment of Negative Symptoms and Cognitive Dysfunction in Patients With Chronic Schizophrenia: Results of a Proof of Concept Study[NCT00148616] | Phase 3 | 13 participants (Actual) | Interventional | 2004-04-30 | Terminated | ||
| Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism[NCT00287820] | Phase 4 | 46 participants (Anticipated) | Interventional | 2004-02-29 | Completed | ||
| A Double-Blind, Placebo-Controlled Random Order Crossover Study of Iloperidone for Symptoms of Arousal in PTSD Including Insomnia and Irritability.[NCT01917318] | Phase 2 | 1 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to Enrollment challenges - Single participant discontinued after placebo, no relevant outcome measure data was recorded.) | ||
| CSP #504 - Risperidone Treatment for Military Service Related Chronic Post-Traumatic Stress Disorder[NCT00099983] | Phase 2 | 296 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Electronic Schizophrenia Treatment Adherence Registry, eSTAR[NCT00283517] | 2,046 participants (Actual) | Observational | 2003-09-30 | Completed | |||
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| Metformin and Lorcaserin for Weight Loss in Schizophrenia[NCT02796144] | Phase 4 | 71 participants (Actual) | Interventional | 2016-09-30 | Terminated (stopped due to The FDA advised of a possible health risk associated with lorcaserin and the drug is being withdrawn.) | ||
| Relative Effectiveness of Schizophrenia Therapy (REST) Study[NCT01245348] | 1,110 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399] | 60 participants (Actual) | Interventional | 2021-10-25 | Completed | |||
| Clinical Utility of Pharmacogenomics of Psychotropic Medications[NCT03907124] | Phase 4 | 0 participants (Actual) | Interventional | 2019-06-03 | Withdrawn (stopped due to PI left institution prior to recruitment.) | ||
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia[NCT01623713] | Phase 2 | 260 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Switching Antipsychotics: Abrupt Discontinuation Versus Overlap[NCT02640300] | Phase 4 | 33 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| E-SMART: Examining Strategy Monitoring and Remediation Training for Schizophrenia[NCT04756388] | 90 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
| Virtual Cognitive Behavioural Therapy for Psychosis: A Randomized Controlled Trial[NCT04752449] | 60 participants (Anticipated) | Interventional | 2021-02-01 | Recruiting | |||
| Effects of Adding Transcranial Direct Current Stimulation to Executive Function Training for Schizophrenia-spectrum Disorders - a Randomized Control Trial[NCT05389345] | 40 participants (Anticipated) | Interventional | 2021-05-01 | Recruiting | |||
| Optimizing Rehabilitation for Phantom Limb Pain Using Mirror Therapy and Transcranial Direct Current Stimulation (tDCS)[NCT02487966] | 132 participants (Actual) | Interventional | 2015-07-31 | Active, not recruiting | |||
| Risperidone in the Treatment of Chronic Schizophrenic Patients: an International Multicentre Double-blind Parallel-group Comparative Study Versus Haloperidol.[NCT00249119] | Phase 3 | 1,579 participants (Actual) | Interventional | Completed | |||
| Risperidone Versus Haloperidol Versus Placebo in the Treatment of Chronic Schizophrenia[NCT00249132] | Phase 3 | 523 participants (Actual) | Interventional | Completed | |||
| An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Intensity of Suicidal Ideation was monitored over the course of the trial by the second section of the Columbia Suicide Severity Rating Scale (CSSRS). This section is only administered if the patient answers yes to the first section. The section consists of 5 questions that refer to the most severe level of ideation endorsed in the first section of the CSSRS. The total score ranges from 2 to 25, with a higher number indicating more intense ideation and greater risk.~Only lifetime intensity of suicidal ideation was explored as the patient had no suicidal ideation from the month prior to beginning the study to the completion of the study" (NCT01917318)
Timeframe: Baseline
| Intervention | score on a scale (Number) |
|---|---|
| Placebo / Iloperidone | 16 |
Aggression was measured by the Modified Overt Aggression Scale (MOAS).This assessment measures four types of aggressive behavior (verbal, aggression against property, autoaggression, and physical aggression) . Total scores on the MOAS range from 0-40, with a higher score indicating more aggressive behavior. (NCT01917318)
Timeframe: Randomization and 8 weeks of treatment, during both treatment periods
| Intervention | units on a scale (Number) | |||
|---|---|---|---|---|
| MOAS at randomization 1 | MOAS after 8 weeks with placebo | MOAS at randomization 2 | MOAS after 2 weeks with iloperidone treatment | |
| Placebo / Iloperidone | 1 | 0 | 0 | 0 |
"The Clinician-Administered PTSD Scale (CAPS) is a structured interview used to diagnose and assess PTSD. Part B of CAPS evaluates symptoms of re-experiencing. Part D evaluates avoidance and numbing.~CAPS-B scores range from 0 to 40 where higher scores indicate more symptoms. A score 0 means no re-experiencing symptoms.~CAPS-D scores range form 0 to 56 and higher scores indicate more symptoms. A score 0 means no avoidance or numbing symptoms.~The primary endpoint was changes in CAPS part B and D after 8 weeks of treatment." (NCT01917318)
Timeframe: Randomization and at the end of each treatment period. Placebo treatment lasted 8 weeks. Iloperidone treatment lasted 2 weeks.
| Intervention | units on a scale (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| CAPS part B at randomization 1 | CAPS part B after 8 weeks with placebo | CAPS part B at randomization 2 | CAPS part B after 2 weeks with iloperidone | CAPS part D at randomization 1 | CAPS part D after 8 weeks with placebo | CAPS part D at randomization 2 | CAPS part D after 2 weeks with iloperidone | |
| Placebo / Iloperidone | 20 | 4 | 4 | 0 | 6 | 2 | 7 | 0 |
The presence and severity os suicidal behavior was monitored over the course of the trial by the third section of the Columbia Suicide Severity Rating Scale (CSSRS). This sections consists of questions about 5 suicidal behaviors and non-suicidal self injurious behavior and it can be answered yes or no. The number of participants who experienced suicidal behavior is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal behavior | 1 month prior ro screening | During the course of the study | |
| Placebo / Iloperidone | 0 | 0 | 0 |
The presence of suicidal ideation was monitored over the course of the trial by the first section of the Columbia Suicide Severity Rating Scale (CSSRS). This first section of the scale consists of 5 questions that can be answered yes or no. The number of participants who reported experiencing suicidal ideation is reported. (NCT01917318)
Timeframe: Total course of the study. CSSRS was administered during each study visit. Suicidal ideation during lifetime and during the month prior to screening were also explored
| Intervention | participants (Number) | ||
|---|---|---|---|
| Lifetime suicidal ideation | 1 month prior to screening | Suicidal ideation during the study | |
| Placebo / Iloperidone | 1 | 0 | 0 |
The primary outcome measure for this study was the total score on the 34-item Clinician-Administered PTSD Scale (CAPS). This study was the intent-to-treat analysis of the improvement in PTSD symptoms from baseline to week-24 follow-up as measured by the CAPS. Total score range for the CAPS is 0-136 with higher values representing a worse outcome. This study was powered initially to detect a 9-point difference between the treatment groups in the CAPS change score. (NCT00099983)
Timeframe: 24 Weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Risperidone | -16.3 |
| Sugar Pill | -12.5 |
Change in body weight in participants assigned to lorcaserin monotherapy treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin | -5.18 |
| Placebo | -3.02 |
Change in body weight in participants assigned to lorcaserin/metformin combination treatment and participants assigned to placebo from baseline to last study visit (up to 52 weeks) (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | pounds (Mean) |
|---|---|
| Lorcaserin and Metformin | -13.05 |
| Placebo | -3.02 |
fasting blood glucose (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -4.30 |
| Lorcaserin | -3.27 |
| Placebo | 3.53 |
high-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | 3.8 |
| Lorcaserin | 1.45 |
| Placebo | -0.78 |
glycosylated hemoglobin (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | percentage of glycosylated hemoglobin (Mean) |
|---|---|
| Lorcaserin and Metformin | -0.03 |
| Lorcaserin | 0.07 |
| Placebo | 0.05 |
low-density lipoprotein (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -7.60 |
| Lorcaserin | -10.86 |
| Placebo | -6.83 |
Total Cholesterol (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -9.05 |
| Lorcaserin | -13.45 |
| Placebo | -9.21 |
serum triglycerides (NCT02796144)
Timeframe: Baseline, Last Observed Visit (Up to 52 weeks)
| Intervention | mg/dL (Mean) |
|---|---|
| Lorcaserin and Metformin | -18.60 |
| Lorcaserin | -19.68 |
| Placebo | -3.11 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
The primary endpoint will be the severity of pain measured by changes in PLP from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS pain scale is a simple 10- point scale (0 = ''no pain'', 10 = ''pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -2.84 |
| Active tDCS and Sham Mirror Therapy | -3.35 |
| Sham tDCS and Active Mirror Therapy | -1.78 |
| Sham tDCS and Sham Mirrory Therapy | -2.58 |
The endpoint will be the severity of pain measured by changes in Phantom Limb Sensation from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Sensation scale is a simple 10- point scale (0 = ''no Phantom Limb Sensation'', 10 = ''Phantom Limb Sensation as much as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.86 |
| Active tDCS and Sham Mirror Therapy | -2.55 |
| Sham tDCS and Active Mirror Therapy | -1.35 |
| Sham tDCS and Sham Mirrory Therapy | -2.83 |
The endpoint will be the severity of pain measured by changes in Stump Pain from baseline to 4 weeks (value at 4 weeks minus value at baseline), as indexed by a Visual Analog Scale (VAS). The VAS Phantom Limb Stump Pain scale is a simple 10- point scale (0 = ''no Phantom Limb Stump Pain'', 10 = ''Phantom Limb Stump Pain as bad as you can imagine''). Since we are using a difference, smaller values (negative) represent a better outcome. (NCT02487966)
Timeframe: 4 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active tDCS and Active Mirror Therapy | -1.31 |
| Active tDCS and Sham Mirror Therapy | -1.9 |
| Sham tDCS and Active Mirror Therapy | -0.91 |
| Sham tDCS and Sham Mirrory Therapy | -0.96 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | mg/dL (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 5 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
| Intervention | microIU/L (Mean) |
|---|---|
| Clozapine Treatment With Adjunctive Ziprasidone | 1 |
| Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
12 reviews available for risperidone and Chronic Disease
| Article | Year |
|---|---|
Evidence-based treatments for youths with severely dysregulated mood: a qualitative systematic review of trials for SMD and DMDD.
Topics: Adolescent; Antipsychotic Agents; Chronic Disease; Evidence-Based Medicine; Female; Humans; Irritabl | 2017 |
[Risk of type 2 diabetes mellitus among users of atypical antipsychotic drugs or conventional treatment: systematic review and meta-analysis].
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Diabetes Mellitus, Type 2; Humans; Mental Disorder | 2009 |
Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
Topics: Acute Disease; Antipsychotic Agents; Chronic Disease; Humans; Risperidone; Schizophrenia | 2004 |
Risperidone long-acting injection: a brief overview.
Topics: Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Humans; Risperidone; Schizophren | 2004 |
N-acetyl-aspartate levels in the dorsolateral prefrontal cortex in the early years of schizophrenia are inversely related to disease duration.
Topics: Adult; Age Factors; Antipsychotic Agents; Aspartic Acid; Choline; Chronic Disease; Creatine; Female; | 2005 |
Chronic restlessness with antipsychotics.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Cholinergic Antagonists; Chro | 2007 |
Chronic schizophrenia. Options for pharmacologic management.
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Drug Therapy, Combination; Humans; Lithium; Psycho | 1995 |
Spontaneous and drug-induced movement disorders in schizophrenia.
Topics: Antipsychotic Agents; Cholinergic Antagonists; Chronic Disease; Dose-Response Relationship, Drug; Dy | 1996 |
New antipsychotic medications: strategies for evaluation and selected findings.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; Clozapine; Drug Ad | 1997 |
Amisulpride: a review of its efficacy in schizophrenia.
Topics: Acute Disease; Amisulpride; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chronic Disease; C | 2000 |
Safety profile of amisulpride in short- and long-term use.
Topics: Amisulpride; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Drug Administration Sc | 2000 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
89 trials available for risperidone and Chronic Disease
| Article | Year |
|---|---|
Efficacy and safety of TV-46000, a long-acting, subcutaneous, injectable formulation of risperidone, for schizophrenia: a randomised clinical trial in the USA and Bulgaria.
Topics: Adult; Antipsychotic Agents; Bulgaria; Chronic Disease; Double-Blind Method; Female; Humans; Male; M | 2023 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
Acute and Long-term Memantine Add-on Treatment to Risperidone Improves Cognitive Dysfunction in Patients with Acute and Chronic Schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Attention; Chronic Disease; Double-Blind Method; Drug Th | 2020 |
A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2013 |
A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Excita | 2014 |
Differences in treatment effect among clinical subgroups in a randomized clinical trial of long-acting injectable risperidone and oral antipsychotics in unstable chronic schizophrenia.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Chronic Disease; Drug Administration Schedu | 2014 |
Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Drug Admini | 2014 |
Symptom structure and severity: a comparison of responses to the positive and negative syndrome scale (PANSS) between patients with PTSD or schizophrenia.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Combat Disorders; Diagnosis, | 2014 |
Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; | 2014 |
L-lysine as an adjunct to risperidone in patients with chronic schizophrenia: a double-blind, placebo-controlled, randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Depression; Double-Blind Method; Female; Follow-Up Stu | 2014 |
Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.
Topics: Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Depressive | 2015 |
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
Topics: Adolescent; Adult; Aged; Alcoholism; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbi | 2015 |
The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2016 |
Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Topics: Adolescent; Adult; Antipsychotic Agents; Capsules; Chronic Disease; Double-Blind Method; Drug Therap | 2008 |
A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Donepezil; Double-Blind Method; Female; Humans; Indans | 2008 |
Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
Topics: Adult; Antipsychotic Agents; Case-Control Studies; Chronic Disease; Cognition Disorders; Double-Blin | 2009 |
Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Cholesterol; Chronic Disease; Dibenz | 2009 |
Results of phase 3 of the CATIE schizophrenia trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cloza | 2009 |
Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans | 2009 |
Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Chronic Disease; | 2009 |
Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients.
Topics: Administration, Oral; Adult; Aged; Antipsychotic Agents; Carbohydrates; Chronic Disease; Delayed-Act | 2010 |
Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Pressure; Body Mass Index; Chronic Disease; Double-Blin | 2010 |
Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognition Disorders; Delayed-Action Preparations; Dose | 2011 |
A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Buspirone; Chronic Disease; Double-Blind Method; Drug Therapy, Combinat | 2010 |
Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial.
Topics: Adenosine; Adenosine Deaminase; Adult; Chronic Disease; Clozapine; Double-Blind Method; Female; Halo | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial.
Topics: Adult; Afghan Campaign 2001-; Chronic Disease; Depression; Double-Blind Method; Drug Resistance; Fem | 2011 |
A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Chronic Diseas | 2012 |
First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Substitution; F | 2011 |
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database.
Topics: Adolescent; Adult; Antipsychotic Agents; Australia; Chronic Disease; Delayed-Action Preparations; Fe | 2012 |
Predicting a 'combined treatment outcome' in chronic schizophrenia: the role of demographics, symptomatology, functioning and subjective well-being.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Demography; Dose-Response Relationshi | 2013 |
Fluvoxamine augmentation in risperidone-resistant schizophrenia: an open trial.
Topics: Antipsychotic Agents; Chronic Disease; Drug Interactions; Drug Therapy, Combination; Female; Fluvoxa | 2002 |
Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.
Topics: Adolescent; Adult; Aged; Amisulpride; Analysis of Variance; Chi-Square Distribution; Chronic Disease | 2002 |
Risperidone in chronic schizophrenia: a detailed audit, open switch study and two-year follow-up of patients on depot medication.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Female; | 2002 |
Emotion perception in schizophrenia: an eye movement study comparing the effectiveness of risperidone vs. haloperidol.
Topics: Adult; Antipsychotic Agents; Attention; Chronic Disease; Emotions; Eye Movements; Facial Expression; | 2003 |
[Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia].
Topics: Antipsychotic Agents; Chronic Disease; Depression; Double-Blind Method; Dyskinesia, Drug-Induced; Fl | 2003 |
Treatment outcome in patients with chronic schizophrenia during long-term administration with risperidone.
Topics: Adolescent; Adult; Chronic Disease; Cohort Studies; Confidence Intervals; Drug Administration Schedu | 2004 |
Adjunctive risperidone treatment in combat veterans with chronic PTSD.
Topics: Antipsychotic Agents; Chronic Disease; Combat Disorders; Drug Therapy, Combination; Humans; Male; Mi | 2004 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Body Mass Index; Chronic Disease; Co | 2005 |
Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
Topics: Adult; Agranulocytosis; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cross-Ove | 2006 |
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Cross-Over Studies; Dibe | 2006 |
Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Chronic Disease; Double-Blind Method; Fem | 2006 |
Differential early onset of therapeutic response with risperidone vs conventional antipsychotics in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clopenthixol; Double-Blind Method; Female; Haloperidol; Human | 2006 |
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Blood Glucose; Chronic Disease; Delayed-Acti | 2007 |
Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; Basal Ganglia Diseases; Celeco | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Topics: Adaptation, Psychological; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Dibenz | 2007 |
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2007 |
Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Data Interpretation, Statistical; De | 2007 |
[Clinical observation on effect of modified Daotan Decoction combined with small dose risperidone in treating chronic schizophrenia].
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Diagnosis, Differential; Drug Therapy, Com | 2007 |
Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2008 |
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Chronic Disease; Cohort S | 2008 |
A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female | 2008 |
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Comorbidity; Dibenzothiazepines; Doub | 2008 |
Efficacy of risperidone on positive features of schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Haloperidol; Humans; Isoxazoles; | 1994 |
Pharmacokinetics of risperidone in chronic schizophrenic patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Cross-Over Studies; Humans; Isoxazoles; Ma | 1994 |
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; Haloperidol; Hum | 1995 |
Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind Method; | 1995 |
Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series.
Topics: Aged; Bipolar Disorder; Chronic Disease; Comorbidity; Dementia; Female; Hospitalization; Humans; Hyp | 1995 |
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Double-Blind M | 1993 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial.
Topics: Adolescent; Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Isoxazoles; Ma | 1993 |
Efficacy of risperidone in reducing positive and negative symptoms in medication-refractory schizophrenia: an open prospective study.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Female; Hospitalization; Humans; Male; Prospective Stu | 1996 |
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Canada; Chronic Disease; Cost-Benefit Analysis; Doubl | 1997 |
Effects of risperidone on polydipsia in chronic schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Behavior Therapy; Chronic Disease; Combined Modality Therapy; Double-Bl | 1997 |
Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland.
Topics: Adult; Antipsychotic Agents; Austria; Basal Ganglia Diseases; Chronic Disease; Double-Blind Method; | 1997 |
Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Clozapine; Double-Blind Method; Drug | 1998 |
Efficacy and tolerability of risperidone in chronic schizophrenic Thai patients.
Topics: Adult; Aged; Analysis of Variance; Chronic Disease; Female; Humans; Male; Middle Aged; Psychological | 1998 |
Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.
Topics: Adult; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Interactions; Drug Th | 1996 |
Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Chronic Disease; D | 1998 |
Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; Double-Blind Method | 1999 |
Comparison of risperidone and mosapramine addition to neuroleptic treatment in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Behavioral Symptoms; Benzazepines; Chronic Diseas | 1999 |
Risperidone addition in serotonin reuptake inhibitor-resistant trichotillomania: three cases.
Topics: Adult; Chronic Disease; Drug Resistance; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; | 1999 |
Risperidone-induced increase of plasma norepinephrine is not correlated with symptom improvement in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 1999 |
A naturalistic study of risperidone maintenance treatment of outpatients with severe mental illness.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Drug Administration | 1999 |
Longitudinal comparative study of risperidone and conventional neuroleptics for treating patients with schizophrenia. The Quebec Schizophrenia Study Group.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Female; Humans; Long | 2000 |
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis. On behalf of the Risperidone Working Group.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Delusions; Dyskinesia, Drug-I | 2000 |
Comparison of risperidone and other neuroleptics in the management of chronic schizophrenia using cognitive therapy.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Cognitive Behavioral Therapy; Female; Humans; Male; Mi | 2000 |
Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chromatography, High Pressure | 2001 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis.
Topics: Adult; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospitalization; Humans; Length of | 2001 |
Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Humans; Male | 2001 |
A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clozapine; D | 2001 |
Risperidone treatment of outpatients with schizophrenia: no evidence of sex differences in treatment response.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Chronic Disease; Dose-Response Relationship, Drug; Drug Ad | 2001 |
Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
Topics: Adult; Antipsychotic Agents; Asian People; Chronic Disease; Double-Blind Method; Female; Haloperidol | 2001 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia.
Topics: Adult; Chronic Disease; Humans; Male; Middle Aged; Prognosis; Prolactin; Psychiatric Status Rating S | 2002 |
The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability.
Topics: Antipsychotic Agents; Chronic Disease; Cross-Cultural Comparison; Double-Blind Method; Haloperidol; | 1992 |
Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study.
Topics: Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Female; Haloperidol; Hospit | 1992 |
Ventricular enlargement, clinical correlates and treatment outcome in chronic schizophrenic inpatients.
Topics: Adult; Aged; Antipsychotic Agents; Brain; Cerebral Ventricles; Chronic Disease; Dilatation, Patholog | 1992 |
Risperidone: clinical development: north American results.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Humans; Isoxazo | 1992 |
71 other studies available for risperidone and Chronic Disease
| Article | Year |
|---|---|
Characteristics of White Matter Structural Networks in Chronic Schizophrenia Treated With Clozapine or Risperidone and Those Never Treated.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clozapine; Cognitive Dysfunction; Diffusion Tensor Ima | 2020 |
Differential effects of different antipsychotic drugs on cognitive function in patients with chronic schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Case-Control Studies; Chronic Disease; Clozapine; Cog | 2020 |
Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2017 |
Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit An | 2013 |
Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Decision Suppo | 2013 |
Dopamine D(2)/D(3) receptor binding of [(123)I]epidepride in risperidone-treatment chronic MK-801-induced rat schizophrenia model using nanoSPECT/CT neuroimaging.
Topics: Animals; Benzamides; Chronic Disease; Disease Models, Animal; Dizocilpine Maleate; Male; Multimodal | 2014 |
Pharmacoeconomics of long-acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Economi | 2016 |
Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Chronic Disease; Clozapine; Computer Simulation | 2015 |
Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cost-Benefit Analysis; Delayed-Action Prepar | 2016 |
Clinical experiences and clinical trials.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dyskinesia, Drug-Induced; Humans; Olanzapine | 2008 |
Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Cholinergic Antagonists; | 2008 |
Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Endpoint Determination; F | 2010 |
Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Chronic Disease; Female; Humans; Injections; Male; Middle A | 2010 |
Effect of risperidone on acute methamphetamine-induced hyperthermia in rats.
Topics: Acute Disease; Animals; Chronic Disease; Fever; Male; Methamphetamine; Rats; Rats, Wistar; Risperido | 2010 |
Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation.
Topics: Anhedonia; Animals; Antipsychotic Agents; Benzodiazepines; Brain; Chronic Disease; Dibenzocyclohepte | 2011 |
Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats.
Topics: Animals; Antipsychotic Agents; C-Reactive Protein; Chronic Disease; Cytokines; Diet, Fat-Restricted; | 2011 |
Chronic Cotard's syndrome: recovery from 2 years' bed-ridden status.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Chronic Disease; Delusions; Drug The | 2011 |
The challenges of clinical psychopharmacological management.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Community Mental Health Services; Comorbidity; Coopera | 2012 |
13C-phenylalanine breath test detects altered phenylalanine kinetics in schizophrenia patients.
Topics: Adult; Animals; Antipsychotic Agents; Breath Tests; Carbon Isotopes; Chronic Disease; Dopamine; Halo | 2012 |
Priapism associated with two atypical antipsychotic agents.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Humans; Male; Piperazines; Priapism; Risperidone; Schi | 2002 |
Cerebral metabolism and risperidone treatment in schizophrenia.
Topics: Adult; Antipsychotic Agents; Cerebellum; Cerebral Cortex; Chronic Disease; Energy Metabolism; Female | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Clozapine; Cohort Effect; Cohort Studies; Haloperidol; Humans | 2003 |
Comparative effectiveness of antipsychotic drugs.
Topics: Antipsychotic Agents; Chronic Disease; Cohort Effect; Dose-Response Relationship, Drug; Drug Adminis | 2003 |
Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials | 2003 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
Topics: Antipsychotic Agents; Chronic Disease; Fluoxetine; Humans; Male; Middle Aged; Obsessive-Compulsive D | 2003 |
Risperidone-induced retrograde ejaculation: case report and review of the literature.
Topics: Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Ejaculation; Humans; Male; | 2004 |
A 17-year-old boy previously diagnosed with chronic Lyme disease. Patient complained of low-grade fevers, headaches, pharyngitis, and suspected his mother was trying to poison him.
Topics: Adolescent; Antipsychotic Agents; Chronic Disease; Diagnosis, Differential; Headache; Humans; Lyme D | 2004 |
Treatment of a rare psychopathological phenomenon: tactile hallucinations and the delusional other.
Topics: Aged; Anticonvulsants; Antipsychotic Agents; Carbamazepine; Chronic Disease; Delusions; Drug Therapy | 2004 |
Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Cholinergic Antagonists; Chronic Dise | 2005 |
Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea.
Topics: Adolescent; Analysis of Variance; Child; Chronic Disease; Female; Humans; Korea; Male; Risperidone; | 2005 |
Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia.
Topics: Adult; Antipsychotic Agents; Atrophy; Brain; Chronic Disease; Clozapine; Female; Follow-Up Studies; | 2005 |
Homocysteine levels and glucose metabolism in non-obese, non-diabetic chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Blood Pressure; Chronic Disease; Clozap | 2006 |
Improved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial response.
Topics: Antipsychotic Agents; Chronic Disease; Delayed-Action Preparations; Humans; Male; Middle Aged; Rispe | 2006 |
Comparison between risperidone, olanzapine, and clozapine in the management of chronic schizophrenia: a naturalistic prospective 12-week observational study.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Weig | 2006 |
Adjunctive risperidone treatment and sleep symptoms in combat veterans with chronic PTSD.
Topics: Aged; Antipsychotic Agents; Chronic Disease; Combat Disorders; Drug Therapy, Combination; Dyssomnias | 2006 |
Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Clozapine; Female; Humans; | 2007 |
Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia.
Topics: Adult; Aged; Anti-Dyskinesia Agents; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced | 2006 |
Alteration in serum neural cell adhesion molecule in patients of schizophrenia.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Chronic Disease; Diben | 2007 |
Risperidone-induced priapism.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Overdose; Erect | 2007 |
Impairment in error monitoring predicts poor executive function in schizophrenia patients.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cognition Disorders; Diagn | 2007 |
Risperidone for chronic schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Humans; Isoxazoles; Piperidines; Ri | 1994 |
Risperidone-induced priapism.
Topics: Antipsychotic Agents; Chronic Disease; Drug Therapy, Combination; Humans; Isoxazoles; Lithium Carbon | 1994 |
Re: Hypomania associated with risperidone.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Female; Humans; Isoxazoles; Piperidi | 1995 |
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chronic Dise | 1995 |
Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders.
Topics: Adult; Age Factors; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Dr | 1995 |
Risperidone response after no clozapine response.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clozapine; Humans; Male; Psychiatric Status Rating Sca | 1995 |
Risperidone in schizophrenia.
Topics: Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Humans; Long-Term Care; Ris | 1996 |
A naturalistic outcome study of risperidone treatment among hospital patients.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Depressive Disorder; Female; Hospita | 1996 |
Outcome of risperidone therapy in elderly patients with chronic psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Humans; Inpatients; Male; Psychotic | 1996 |
Self-induced water intoxication treated with risperidone.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Drinking; Humans; Male; Middle Aged; Prospective Studi | 1996 |
[Compliance determines therapeutic success in schizophrenia. Strategy in initial therapy].
Topics: Chronic Disease; Clozapine; Humans; Patient Compliance; Risperidone; Schizophrenia | 1995 |
Chronic schizophrenia: response to clozapine, risperidone, and paroxetine.
Topics: Chronic Disease; Clozapine; Drug Therapy, Combination; Humans; Middle Aged; Paroxetine; Risperidone; | 1997 |
Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Administratio | 1996 |
Impact of risperidone on the use of mental health care resources.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antipsychotic Agents; California; Chronic Disease; Cost-Be | 1997 |
Mania induced by risperidone: dose related?
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Dose-Response Relationship, Drug; Fe | 1998 |
Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Dy | 1998 |
Prolactogenic effects of risperidone in male patients--a preliminary study.
Topics: Antipsychotic Agents; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedul | 1998 |
Manic and psychotic symptoms following risperidone withdrawal in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Bipolar Disorder; Chronic Disease; Humans; Male; Psychoses, Substance-I | 1998 |
Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone.
Topics: Antipsychotic Agents; Baltimore; Chronic Disease; Delayed-Action Preparations; Disease-Free Survival | 1998 |
Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia.
Topics: Adult; Antipsychotic Agents; Aspartic Acid; Chronic Disease; Clozapine; Creatine; Female; Gyrus Cing | 2000 |
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Hospitalization; Humans; Isra | 2001 |
Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Chronic Disease; Cytochrome P-450 CYP2 | 2001 |
Combination risperidone and quetiapine therapy in refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dibenzothiazepines; Drug Therapy, Combination; Humans; | 2001 |
Long-term treatment of chronic schizophrenia with risperidone: a study with plasma levels.
Topics: Adult; Age Factors; Antipsychotic Agents; Brief Psychiatric Rating Scale; Chromatography, High Press | 2001 |
Addition of risperidone to clozapine therapy in chronically psychotic inpatients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Clozapine; Drug Therapy, Combination; Female; Hospital | 2001 |
Hyperthermia and chronic pancerebellar syndrome after cocaine abuse.
Topics: Adult; Antipsychotic Agents; Cerebellar Diseases; Chronic Disease; Cocaine-Related Disorders; Diagno | 2001 |
Risperidone added to clozapine: impact on serum prolactin levels.
Topics: Adult; Age of Onset; Ambulatory Care; Antipsychotic Agents; Chronic Disease; Clozapine; Cross-Sectio | 2001 |
Service use and costs of treating schizophrenia with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cost-Benefit Analysis; Dos | 2001 |
Would a switch from typical antipsychotics to risperidone be beneficial for elderly schizophrenic patients? A naturalistic, long-term, retrospective, comparative study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Chronic Disease; Female; Humans; Long-Term Care; Male | 2002 |
Efficacy and tolerability of a new antipsychotic compound (risperidone): results of a pilot study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Female; Humans; Isoxazoles; Male; Middl | 1991 |